Inflammatory bowel disease: Can omega-3 fatty acids really help?

Annals of Gastroenterology

Volumn 29, Issue 1, 2016, Pages 37-43

  Barbalho, Sandra Maria ^a   Goulart, Ricardo De Alvares ^b   Quesada, Karina ^a   Bechara, Marcelo Dib ^a   De Carvalho, Antonely De Cássio Alves ^c  

^a Universidade de Marilia   (Brazil)

^b University Hospital   (Brazil)

^c University of Marília ^*  (Brazil)

Author keywords

Crohn s disease; Omega 3 polyunsaturated fatty acids; Ulcerative colitis

Indexed keywords

DOCOSAHEXAENOIC ACID; FATTY ACID DERIVATIVE; ICOSAPENTAENOIC ACID; LINOLENIC ACID; OMEGA 3 FATTY ACID; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; FAT INTAKE; HUMAN; INFLAMMATORY BOWEL DISEASE; NONHUMAN; NUTRITIONAL REQUIREMENT; PATHOGENESIS; PATHOPHYSIOLOGY; REMISSION; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

EID: 84953874405     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Stark AK, Sriskantharajah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharmacol 2015;23:82-91
2. Guerra I, Bermejo F. Biosimilars in inflamatory bowel disease: Management and care. Rev Esp Enferm Dig 2015;107:389
3. Nee J, Feuerstein JD. Optimizing the care and health of women with inflammatory bowel disease. Gastroenterol Res Pract 2015;2015:435-820
4. Elia PP, Tolentino YF, Bernardazzi C, de Souza HS. The role of innate immunity receptors in the pathogenesis of inflammatory bowel disease. Mediators Inflamm 2015;2015:936-193
5. Andrade ME, Araújo RS, de Barros PA, et al. The role of immunomodulators on intestinal barrier homeostasis in experimental models. Clin Nutr 2015;34:1080-1087
6. Victoria CR, Sassaki LY, Nunes HRC. Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil. Arq Gastroenterol 2009;46:20-25
7. Nguyena DL, Leea JG, Parekha NK, Samarasenaa J, Bechtoldb ML, Chang K. The current and future role of endomicroscopy in the management of inflammatory bowel disease. Ann Gastroenterol 2015;28:331-336
8. Tabbaa M, Golubic M, Roizen MF, Bernstein AM. Docosahexaenoic acid, inflammation, and bacterial dysbiosis in relation to periodontal disease, inflammatory bowel disease, and the metabolic syndrome. Nutrients 2013;5:3299-3310
9. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol 2005;19(Suppl A):5-36
10. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606-1619
11. Cheifetz AS. Management of active Crohn disease. J Am Med Association 2013;309:2150-2158
12. Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 2011;5:185-210
13. Prüfer J, Schuchardt M, Tölle M, et al. Harmful effects of the azathioprine metabolite 6-mercaptopurine in vascular cells: induction of mineralization. PLoS One 2014;9:e101709
14. Shores DR, Binion DG, Freeman BA, Baker PR. New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease. Inflamm Bowel Dis 2011;17:2192-2204
15. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol 2009;104:465-483
16. Dixon LJ, Kabi A, Nickerson KP, McDonald C. Combinatorial effects of diet and genetics on inflammatory bowel disease pathogenesis. Inflamm Bowel Dis 2015;21:912-922
17. Reif S, Klein I, Lubin F, Farbstein M, Hallak A, Gilat T. Pre-illness dietary factors in inflammatory bowel disease. Gut 1997;40:754-760
18. Russel MG, Engels LG, Muris JW, et al. Modern life in the epidemiology of inflammatory bowel disease: A case-control study with special emphasis on nutritional factors. Eur J Gastroenterol Hepatol 1998;10:243-249
19. Frolkis A, Dieleman LA, Barkema HW, et al. Environment and the inflammatory bowel diseases. Can J Gastroenterol 2013;27:e18-e24
20. Sung MK, Park MY. Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view. World J Gastroenterol 2013;19:994-1004
21. Pfeffer-Gik T, Levine A. Dietary clues to the pathogenesis of Crohn’s disease. Dig Dis 2014;32:389-394
22. Hou TY, McMurray DN, Chapkin RS. Omega-3 fatty acids, lipid raft s, and T cell signaling. Eur J Pharmacol 2015 [Epub ahead of print].
23. Farzaei MH, Rahimi R, Abdollahi M. The role of dietary polyphenols in the management of inflammatory bowel disease. Curr Pharm Biotechnol 2015;16:196-210
24. Jantchou P, Morois S, Clavel-Chapelon F, Boutron-Ruault M-C, Carbonnel F. Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study. Am J Gastroenterol 2010;105:2195-2201
25. Ananthakrishnan AN, Khalili H, De Silva PS. Higher dietary fiber intake is associated with lower risk of Crohn’s disease but not ulcerative colitis – a prospective study. Gastroenterology 2010;142(Suppl 1):S-148
26. Calder PC. Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta 2015;1851:469-484
27. Lorente-Cebrián S, Costa AG, Navas-Carretero S, et al. An update on the role of omega-3 fatty acids on inflammatory and degenerative diseases. J Physiol Biochem 2015;71:341-349
28. Generoso SV, Rodrigues NM, Trindade LM, et al. Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice. Lipids Health Dis 2015;14:54
29. Martin FP, Lichti P, Bosco N, et al. Metabolic phenotyping of an adoptive transfer mouse model of experimental colitis and impact of dietary fish oil intake. J Proteome Res 2015;14:1911-1919
30. Farrukh A, Mayberry JF. Is there a role for fish oil in inflammatory bowel disease? World J Clin Cases 2014;2:250-252
31. DiNicolantonio JJ, Niazi AK, McCarty MF, O’Keefe JH, Meier P, Lavie CJ. Omega-3s and cardiovascular health. Ochsner J 2014;14:399-412
32. Lewis EJ, Radonic PW, Wolever TM, Wells GD. 21 days of mammalian omega-3 fatty acid supplementation improves aspects of neuromuscular function and performance in male athletes compared to olive oil placebo. J Int Soc Sports Nutr 2015;12:28
33. Barbalho SM, Bechara MD, Quesada K, Goulart RA. Omega 3 fatty acid and the resolution of inflammatory processes. Medicina 2011;44:234-240
34. Duivenvoorde LP, van Schothorst EM, Swarts HM, et al. A difference in fatty acid composition of isocaloric high-fat diets alters metabolic flexibility in male C57BL/6JOlaHsd mice. PLoS One 2015;10:e0128515
35. Duivenvoorde LP, van Schothorst EM, Derous D, et al. Oxygen restriction as challenge test reveals early high-fat-diet-induced changes in glucose and lipid metabolism. Pflugers Arch 2015;467:1179-1193
36. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. J Am Med Assoc 2012;308:1024-1033
37. Din JN, Newby DE, Flapan AD. Omega 3 fatty acids and cardiovascular disease-fishing for a natural treatment. BMJ 2004;328:30-35
38. Gdula-Argasińska J, Czepiel J, Woźniakiewicz A, et al. n-3 Fatty acids as resolvents of inflammation in the A549 cells. Pharmacol Rep 2015;67:610-615
39. White PJ, Mitchell PL, Schwab M, et al. Transgenic ω-3 PUFA enrichment alters morphology and gene expression profile in adipose tissue of obese mice: Potential role for protectins. Metabolism 2015;64:666-676
40. Shevalye H, Yorek MS, Coppey LJ, et al. Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes. J Neurophysiol 2015;114:199-208
41. Arisue A, Shimojima N, Tomiya M, et al. Effect of an omega-3 lipid emulsion in reducing oxidative stress in a rat model of intestinal ischemia−reperfusion injury. Pediatr Surg Int 2012;28:913-918
42. Fiala M, Halder RC, Sagong B, et al. ω-3 Supplementation increases amyloid-β phagocytosis and resolvin D1 in patients with minor cognitive impairment. FASEB J 2015;29:2681-2689
43. Wang X, Hjorth E, Vedin I, et al. Effects of n-3 FA supplementation on the release of pro-resolving lipid mediators by blood mononuclear cells: the OmegAD study. J Lipid Res 2015;56:674-681
44. Seki H, Sasaki T, Ueda T, Arita M. Resolvins as regulators of the immune system. Sci World J 2010;10:818-831
45. Salem N Jr, Eggersdorfer M. Is the world supply of omega-3 fatty acids adequate for optimal human nutrition? Curr Opin Clin Nutr Metab Care 2015;18:147-154
46. Kris-Etherton PM, Innis S, Ammerican Dietetic Assocition, Dietitians of Canada. Position of the American Dietetic Association and Dietitians of Canada: dietary fatty acids. J Am Diet Assoc 2007;107:1599-1611
47. Uchiyama K, Nakamura M, Odahara S, et al. N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1696-1707
48. Bento AF, Claudino RF, Dutra RC, Marcon R, Calixto JB. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol 2011;187:1957-1969
49. Liu Y, Chen F, Odle J, Lin X, Jacobi SK, Zhu H, Wu Z. Fish oil enhances intestinal integrity and inhibits TLR4 and NOD2 signaling pathways in weaned pigs aft er LPS challenge. J Nutr 2012;142:2017-2024
50. Gurzell EA, Wiesinger JA, Morkam C, Hemmrich S, Harris WS, Fenton JI. Is the omega-3 index a valid marker of intestinal membrane phospholipid EPA+DHA content? Prostaglandins Leukot Essent Fatty Acids 2014;91:87-96
51. Loeschke K, Ueberschaer B, Pietsch A, et al. n-3 fatty acids only delay early relapse of ulcerative colitis in remission. Dig Dis Sci 1996;41:2087-2094
52. Hawthorne AB, Daneshmend TK, Hawkey CJ, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992;33:922-928
53. Parlato M, Yeretssian G. NOD-like receptors in intestinal homeostasis and epithelial tissue repair. Int J Mol Sci 2014;15:9594-9627
54. Fukata M, Vamadevan AS, Abreu MT. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol 2009;21:242-253
55. Pearl DS, Masoodi M, Eiden M, et al. Altered colonic mucosal availability of n-3 and n-6 polyunsaturated fatty acids in ulcerative colitis and the relationship to disease activity. J Crohns Colitis 2014;8:70-79
56. John S, Luben R, Shrestha SS, Welch A, Khaw KT, Hart AR. Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative colitis: a UK prospective cohort study. Eur J Gastroenterol Hepatol 2010;22:602-606
57. Barbosa DS, Cecchini R, El Kadri MZ, Rodríguez MA, Burini RC, Dichi I. Decreased oxidative stress in patients with ulcerative colitis supplemented with fishoil omega-3 fatty acids. Nutrition 2003;19:837-842
58. Chan SS, Luben R, Olsen A, et al. Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn’s disease. Aliment Pharmacol Ther 2014;39:834-842
59. Chan SS, Hart AR. Commentary: the association between high dietary intake of docosahexaenoic acid and reduced risk of Crohn’s disease-authors’ reply. Aliment Pharmacol Ther 2014;39:1332
60. Piazzi G, D’Argenio G, Prossomariti A, et al. Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota. Int J Cancer 2014;135:2004-2013
61. Dichi I, Frenhane P, Dichi JB, et al. Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis. Nutrition 2000;16:87-90
62. Lev-Tzion R, Griffiths AM, Leder O, Turner D. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2014;2:CD006320
63. Hoshi T, Wissuwa B, Tian Y, et al. Omega-3 fatty acids lower blood pressure by directly activating large-conductance Ca2+-dependent K+ channels. Proc Natl Acad Sci USA 2013;110:4816-4821
64. Marion-Letellier R, Savoye G, Beck PL, Panaccione R, Ghosh S. Polyunsaturated fatty acids in inflammatory bowel diseases: a reappraisal of effects and therapeutic approaches. Inflamm Bowel Dis 2013;19:650-661
65. Ibrahim A, Aziz M, Hassan A, et al. Dietary α-linolenic acid-rich formula reduces adhesion molecules in rats with experimental colitis. Nutrition 2012;28:799-802
66. Tyagi A, Kumar U, Reddy S, et al. Attenuation of colonic inflammation by partial replacement of dietary linoleic acid with α-linolenic acid in a rat model of inflammatory bowel disease. Br J Nutr 2012;108:1612-1622
67. Bosco N, Brahmbhatt V, Oliveira M, et al. Effects of increase in fish oil intake on intestinal eicosanoids and inflammation in a mouse model of colitis. Lipids Health Dis 2013;12:81
68. Tokuyama S, Nakamoto K. Unsaturated fatty acids and pain. Biol Pharm Bull 2011;34:1174-1178
69. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A 2003;100:1751-1756
70. Wagner K, Vito S, Inceoglu B, Hammock BD. The role of long chain fatty acids and their epoxide metabolites in nociceptive signaling. Prostaglandins Other Lipid Mediat 2014;113-115:2-12
71. Pérez J, Ware MA, Chevalier S, Gougeon R, Bennett GJ, Shir Y. Dietary fat and protein interact in suppressing neuropathic painrelated disorders following a partial sciatic ligation injury in rats. Pain 2004;111:297-305
72. Mirnikjoo B, Brown SE, Kim HF, Marangell LB, Sweatt JD, Weeber EJ. Protein kinase inhibition by omega-3 fatty acids. J Biol Chem 2001;276:10888-10896
73. Seung Kim HF, Weeber EJ, Sweatt JD, Stoll AL, Marangell LB. Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Mol Psychiatry 2001;6:246-248
74. Nakamoto K, Nishinaka T, Mankura M, Fujita-Hamabe W, Tokuyama S. Antinociceptive effects of docosahexaenoic acid against various pain stimuli in mice. Biol Pharm Bull 2010;33:1070-1072
75. Nakamoto K, Nishinaka T, Ambo A, Mankura M, Kasuya F, Tokuyama S. Possible involvement of β-endorphin in docosahexaenoic acid-induced antinociception. Eur J Pharmacol 2011;666:100-104
76. Ramsden CE, Zamora D, Makriyannis A, et al. Diet-induced changes in n-3- and n-6-derived endocannabinoids and reductions in headache pain and psychological distress. J Pain 2015;16:707-716
77. Trépanier MO, Hopperton KE, Orr SK, Bazinet RP. N-3 polyunsaturated fatty acids in animal models with neuroinflammation: An update. Eur J Pharmacol 2015 [Epub ahead of print].